India resists calls to use existing compulsory licensing powers for covid drugs
Despite advocacy of TRIPS waiver, the country’s government has expressed reluctance to bypass patent rights
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.